Clinical relevance of curcumin-induced immunosuppression in living-related donor renal transplant: An in vitro analysis

Experimental and Clinical Transplantation

Volumn 8, Issue 2, 2010, Pages

  Bharti, Alok C ^a,b   Panigrahi, Arundhati ^a   Sharma, Prabhat K ^a   Gupta, Nivedita ^a   Kumar, Rakesh ^b   Shukla, Shirish ^b   Bhowmik, Dipankar M ^a   Agarwal, Sanjay K ^a   Guleria, Sandeep ^a   Mehra, Narinder K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

Author keywords

Acute rejection; Chronic rejection; Flow cytometry; Interferon ; Peripheral blood lymphocytes

Indexed keywords

AZATHIOPRINE; CURCUMIN; CYCLOSPORIN; CYTOKINE; GAMMA INTERFERON; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PHORBOL 13 ACETATE 12 MYRISTATE; PREDNISOLONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG SUBSTITUTION; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; TH1 CELL;

EID: 77954118537     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Rodrigues MA, Hutchinson IV, Morris PJ. Alloreactive T suppressor cells in the rat. I. Evidence of three distinct subsets of splenic suppressor T cells resistant to cyclosporine. Transplantation. 1989;47(5):847-852.
2. Ratner LE, Hadley GA, Hanto DW, Mohanakumar T. Immunology of renal allograft rejection. Arch Pathol Lab Med. 1991;115(3):283-287.
3. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation. 1993;55(4):752-756; discussion 756-757.
4. Kaminski ER, Kaminski A, Bending MR, et al. In vitro cytokine profiles and their relevance to rejection following renal transplantation. Transplantation. 1995;60(7):703-706.
5. Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Cook HT, Lechler RI. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy. J Immunol. 2001;167(12):7199-7206.
6. Lehmann M, Graser E, Risch K, et al. Anti-CD4 monoclonal antibody-induced allograft tolerance in rats despite persistence of donor-reactive T cells. Transplantation. 1997;64(8):1181-1187.
7. Halloran PF, Urmson J, Ramassar V, et al. Lesions of T-cell-mediated kidney allograft rejection in mice do not require perforin or granzymes A and B. Am J Transplant. 2004;4(5):705-712.
8. Dallman MJ. Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult. Curr Opin Immunol. 1995;7(5):632-638.
9. Strom TB, Roy-Chaudhury P, Manfro R, et al. The Th1/Th2 paradigm and the allograft response. Curr Opin Immunol. 1996;8(5):688-693.
10. Stinn JL, Taylor MK, Becker G, et al. Interferon-gamma-secreting T-cell populations in rejecting murine cardiac allografts: assessment by flow cytometry. Am J Pathol. 1998;153(5):1383-1392.
11. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems. The differential activation of Th2-like effector cells in peripheral tolerance. Transplantation. 1992;53(6):1281-1294.
12. Alard P, Lantz O, Perrot JY, Chavanel G, Senik A, Charpentier B. A possible role for specific anergy in immunologic hyporeactivity to donor stimulation in human kidney allograft recipients. Transplantation. 1993;55(2):277-283.
13. Basak U, Mitra DK, Panigrahi A, et al. Clinical relevance of monitoring cytokine production following living donor renal transplantation. Transplant Proc. 2003;35(1):404-406.
14. Benvenuto R, Bachetoni A, Cinti P, et al. Enhanced production of interferon-gamma by T lymphocytes cloned from rejected kidney grafts. Transplantation. 1991;51(4):887-890.
15. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenterrandomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation. 1997;64(3):436-443.
16. Ponticelli C. Calcineurin-inhibitors in renal transplantation. Too precious to be abandoned. Nephrol Dial Transplant. 2000;15(9):1307-1309.
17. Samaniego M, Becker BN, Djamali A. Drug insight: maintenance immunosuppression in kidney transplant recipients. Nat Clin Pract Nephrol. 2006;2(12):688-699.
18. Grinyó JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant. 2006;6(9):1991-1999.
19. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation. 2006;82(9):1153-1162.
20. Song AT, Abdala E, Bonazzi PR, Bacchella T, Machado MC. Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?--A mini-review. Braz J Infect Dis. 2006;10(2):132-138.
21. Ranjan D, Johnston TD, Wu G, Elliott L, Bondada S, Nagabhushan M. Curcumin blocks cyclosporine A-resistant CD28 costimulatory pathway of human T-cell proliferation. J Surg Res. 1998;77(2):174-178.
22. Ranjan D, Chen C, Johnston TD, Jeon H, Nagabhushan M. Curcumin inhibits mitogen stimulated lymphocyte proliferation, NFkappaB activation, and IL-2 signaling. J Surg Res. 2004;121(2):171-177.
23. Kang BY, Song YJ, Kim KM, Choe YK, Hwang SY, Kim TS. Curcumin inhibits Th1 cytokine profile in CD4+ T cells by suppressing interleukin-12 production in macrophages. Br J Pharmacol. 1999;128(2):380-384.
24. Natarajan C, Bright JJ. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol. 2002;168(12):6506-6513.
25. Kim HY, Park EJ, Joe EH, Jou I. Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J Immunol. 2003;171(11):6072-6079.
26. Chueh SC, Lai MK, Liu IS, Teng FC, Chen J. Curcumin enhances the immunosuppressive activity of cyclosporine in rat cardiac allografts and in mixed lymphocyte reactions. Transplant Proc. 2003;35(4):1603-1605.
27. Shoskes DA. Effect of bioflavonoids quercetin and curcumin on ischemic renal injury: a new class of renoprotective agents. Transplantation. 1998;66(2):147-152.
28. Shoskes DA, Jones EA, Shahed A. Synergy of mycophenolate mofetil and bioflavonoids in prevention of immune and ischemic injury. Transplant Proc. 2000;32(4):798-799.
29. Jones EA, Shoskes DA. The effect of mycophenolate mofetil and polyphenolic bioflavonoids on renal ischemia reperfusion injury and repair. J Urol. 2000;163(3):999-1004.
30. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood. 2003;101(3):1053-1062.
31. Openshaw P, Murphy EE, Hosken NA, e al. Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. J Exp Med. 1995;182(5):1357-1367.
32. Picker LJ, Singh MK, Zdraveski Z, et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood. 1995;86(4):1408-1419.
33. Mosmann TR, Li L, Hengartner H, Kagi D, Fu W, Sad S. Differentiation and functions of T cell subsets. Ciba Found Symp. 1997;204:148-154; discussion 154-158.
34. Obata F, Yoshida K, Ohkubo M, et al. Contribution of CD4+ and CD8+ T cells and interferon-gamma to the progress of chronic rejection of kidney allografts: the Th1 response mediates both acute and chronic rejection. Transpl Immunol. 2005;14(1):21-25.
35. Gertsch J, Güttinger M, Heilmann J, Sticher O. Curcumin differentially modulates mRNA profiles in Jurkat T and human peripheral blood mononuclear cells. Bioorg Med Chem. 2003;11(6):1057-1063.
36. Yasni S, Yoshiie K, Oda H, Sugano M, Imaizumi K. Dietary Curcuma xanthorrhiza Roxb. increases mitogenic responses of splenic lymphocytes in rats, and alters populations of the lymphocytes in mice. J Nutr Sci Vitaminol (Tokyo). 1993;39(4):345-354.
37. Sikora E, Bielak-Zmijewska A, Piwocka K, Skierski J, Radziszewska E. Inhibition of proliferation and apoptosis of human and rat T lymphocytes by curcumin, a curry pigment. Biochem Pharmacol. 1997;54(8):899-907.
38. Zhang M, Deng CS, Zheng JJ, Xia J. Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin. 2006;27(8):1071-1077.
39. Kobayashi T, Hashimoto S, Horie T. Curcumin inhibition of Dermatophagoides farinea-induced interleukin-5 (IL-5) and granulocyte macrophage-colony stimulating factor (GM-CSF) production by lymphocytes from bronchial asthmatics. Biochem Pharmacol. 1997;54(7):819-824.
40. Csizmadia V, Gao W, Hancock SA, et al. Differential NF-kappaB and IkappaB gene expression during development of cardiac allograft rejection versus CD154 monoclonal antibody-induced tolerance. Transplantation. 2001;71(7):835-840.
41. Finn PW, He H, Ma C, et al. Molecular profiling of the role of the NF-kappaB family of transcription factors during alloimmunity. J Leukoc Biol. 2002;72(5):1054-1062.
42. Finn PW, Stone JR, Boothby MR, Perkins DL. Inhibition of NF-kappaB-dependent T cell activation abrogates acute allograft rejection. J Immunol. 2001;167(10):5994-6001.
43. Azuma H, Tomita N, Kaneda Y, et al. Transfection of NFkappaB-decoy oligodeoxynucleotides using efficient ultrasound-mediated gene transfer into donor kidneys prolonged survival of rat renal allografts. Gene Ther. 2003;10(5):415-425.
44. Vos IH, Govers R, Gröne HJ, et al. NFkappaB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J. 2000;14(5):815-822.
45. Suzuki J, Morishita R, Amano J, Kaneda Y, Isobe M. Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene Ther. 2000;7(21):1847-1852.
46. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23(1A):363-398.
47. Shoskes D, Lapierre C, Cruz-Correa M, et al. Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial. Transplantation. 2005;80(11):1556-1559. Erratum in: Transplantation. 2006;82(5):715.
48. Lee JR, Seok CJ, Kim JS, Chang JM, Seo JW. Expression of NF-kappaB and cytokines in chronic rejection of transplanted murine heart. J Korean Med Sci. 2001;16(4):397-406.
49. Meyer S, Kohler NG, Joly A. Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation. FEBS Lett. 1997;413(2):354-358.
50. Tirkey N, Kaur G, Vij G, Chopra K. Curcumin, a diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys. BMC Pharmacol. 2005;5:15.
51. McGrath LT, Treacy R, McClean E, Brown JH. Oxidative stress in cyclosporin and azathioprine treated renal transplant patients. Clin Chim Acta. 1997;264(1):1-12.
52. Zhong Z, Arteel GE, Connor HD, et al. Cyclosporin A increases hypoxia and free radical production in rat kidneys: prevention by dietary glycine. Am J Physiol. 1998;275(4 Pt 2):F595-F604.
53. Gaedeke J, Noble NA, Border WA. Curcumin blocks fibrosis in anti-Thy 1 glomerulonephritis through up-regulation of heme oxygenase 1. Kidney Int. 2005;68(5):2042-2049.
54. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21(4B):2895-2900.
55. Lao CD, Ruffin MT 4th, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10.